27 clinical trials found.
-
A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RASPhase
TRIAL ROLE: Sub Investigator
-
Phase 1 First-In-Human Study to Explore the Safety Tolerability and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
The tumor-associated antigens mesothelin (MSLN) and cadherin-3 (CDH3) are co-expressed in multiple tumor types, with minimal overlap observed in normal tissues. AMG 305 is a ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 2 Open Label Study of REC-4881 in Participants with Unresectable Locally Advanced or Metastatic Cancer with AXIN1 or APC Mutation
This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants ...Phase
TRIAL ROLE: Sub Investigator
-
AN OPEN-LABEL MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
This is a study of a drug called LOXO-435 for patients with advanced solid tumors, specifically focusing on metastatic urothelial cancer (mUC) that has a ...
Phase
TRIAL ROLE: Sub Investigator
-
A RANDOMIZED PHASE II TRIAL OF ADJUVANT NIVOLUMAB WITH OR WITHOUT CABOZANTINIB IN PATIENTS WITH RESECTED MUCOSAL MELANOMA
A RANDOMIZED PHASE II TRIAL OF ADJUVANT NIVOLUMAB WITH OR WITHOUT CABOZANTINIB IN PATIENTS WITH RESECTED MUCOSAL MELANOMAPhase
TRIAL ROLE: Sub Investigator
-
A Phase 1/1b First-In-Human Multi-Part Open-Label Study to Investigate the Safety Tolerability Pharmacokinetics Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable Recurrent or Metastatic) Solid Tumors
This is a study is testing a new drug called DF6215 on patients with tough-to-treat (unresectable, recurrent or metastatic) solid tumors. The goal is to ...
Phase
TRIAL ROLE: Sub Investigator
-
A Phase I/IIa Open-label Multi-centre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)
This study is a trial to test the tolerability, side effects, and early effectiveness of the drug AZD0022 in patients with advanced tumors that have ...
Phase
TRIAL ROLE: Sub Investigator
